• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Puma Biotechnology (NQ: PBYI )

    2.280 -0.080 (-3.39%)
    Streaming Delayed Price Updated: 2:58 PM EDT, Sep 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Puma Biotechnology

    < Previous 1 2 3 4 5 6 Next >
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
    From Puma Biotechnology, Inc.
    Via Business Wire
    Why Shares of Puma Biotechnology Rose This Week
    The company's CEO bought $2.5 million worth of company stock. 
    Via The Motley Fool
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Releases Updated Corporate Presentation
    From Puma Biotechnology, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Why Puma Biotechnology's Shares Jumped 20% on Monday
    It may have benefited from positive news about another company's drug candidate. 
    Via The Motley Fool
    Why Richardson Electronics Shares Surged Over 8%; Here Are 55 Biggest Movers From Friday
    Gainers AEye, Inc. (NASDAQ: LIDR) shares jumped 50% to close at $1.25 on Friday. AEye recently posted a Q3 loss of $0.11 per share. 
    Via Benzinga
    Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
    Via Benzinga
    S&P 500 Down 1%; Crude Oil Drops Sharply
    U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday. 
    Via Benzinga
    Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
    Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. 
    Via Benzinga
    Short Volatility Alert: Puma Biotechnology, Inc.
    On Tuesday, shares of Puma Biotechnology, Inc. (NASDAQ: PBYI) experienced volatile short activity. After the activity, the stock price went up +3.99% to $3.26. The overall sentiment for PBYI has been... 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Monday
      During Monday's session, 50 stocks hit new 52-week highs. 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Gainers 
    Via Benzinga
    Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
    Gainers 
    Via Benzinga
    Puma Biotechnology Reports Third Quarter 2022 Financial Results
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology's Earnings Outlook
    Puma Biotechnology (NASDAQ:PBYI) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Puma... 
    Via Benzinga
    Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
    Via Benzinga
    Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.